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Abstract: A protocol for evaluating ultrasmall superparamagnetic particles of iron oxide (USPIO)
uptake and elimination in cerebral small vessel disease patients was developed and piloted.
B1-insensitive R1 measurement was evaluated in vitro. Twelve participants with history of minor
stroke were scanned at 3-T MRI including structural imaging, and R1 and R2* mapping. Participants
were scanned (i) before and (ii) after USPIO (ferumoxytol) infusion, and again at (iii) 24–30 h and
(iv) one month. Absolute and blood-normalised changes in R1 and R2* were measured in white
matter (WM), deep grey matter (GM), white matter hyperintensity (WMH) and stroke lesion regions.
R1 measurements were accurate across a wide range of values. R1 (p < 0.05) and R2* (p < 0.01)
mapping detected increases in relaxation rate in all tissues immediately post-USPIO and at 24–30 h.
R2* returned to baseline at one month. Blood-normalised R1 and R2* changes post-infusion and at
24–30 h were similar, and were greater in GM versus WM (p < 0.001). Narrower distributions were
seen with R2* than for R1 mapping. R1 and R2* changes were correlated at 24–30 h (p < 0.01). MRI
relaxometry permits quantitative evaluation of USPIO uptake; R2* appears to be more sensitive to
USPIO than R1. Our data are explained by intravascular uptake alone, yielding estimates of cerebral
blood volume, and did not support parenchymal uptake. Ferumoxytol appears to be eliminated at
1 month. The approach should be valuable in future studies to quantify both blood-pool USPIO and
parenchymal uptake associated with inflammatory cells or blood-brain barrier leak.
Keywords: cerebral small vessel disease; MRI; ferumoxytol; USPIO; inflammation; relaxometry
1. Introduction
Cerebral small vessel disease (SVD) accounts for 20–25% of strokes and increases the risk of
cognitive impairment, disability and dementia. The pathogenesis is poorly understood but several
mechanisms are hypothesised to contribute, including inflammation [1], blood-brain barrier (BBB)
leakage [2] and vessel stiffness [3]. Several magnetic resonance imaging (MRI) methods have been used
to explore microstructural and microvascular properties in SVD, including those utilising intrinsic
tissue contrast (e.g., diffusion tensor imaging to assess white matter integrity) [4], respiratory gas
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challenges (e.g., cerebrovascular reactivity) [5], and gadolinium contrast-based approaches (e.g.,
dynamic contrast-enhanced (DCE) MRI to quantify BBB permeability) [6]. As far as we are aware, no
studies have employed ultrasmall superparamagnetic particles of iron oxide (USPIO) contrast agents
to study SVD. These particles, which have T1, T2 and T2* shortening effects, have several benefits
compared with gadolinium-based contrast agents: (i) a large T2* effect due to the superparamagnetic
nature of the contrast agent, (ii) they may often be used in patients with renal failure, for whom
gadolinium-based agents are contraindicated [7], (iii) slow rates of extravasation and elimination
facilitate convenient MR angiography at high resolution and steady-state cerebral blood volume
(CBV) measurement [8], and (iv) phagocytosis by macrophages, which concentrate in inflamed tissue,
provides an imaging marker of inflammation [9], for example in abdominal aortic aneurysm [10] and
myocardial infarction [11]. However, since inflammatory uptake typically occurs over a longer period
than the MRI examination, multiple examinations are required and quantitative analysis based on
signal changes is therefore impractical.
In this pilot study, we developed and evaluated an MRI relaxometry protocol for assessing USPIO
(ferumoxytol) uptake in patients with cerebral SVD. We measured R2* using the three dimensional
multiple-spoiled-gradient-echo technique. Volumetric mapping of R1 within a feasible scan time
is challenging at 3T, where increased B1 inhomogeneity impairs the accuracy of the widely-used
and widely-available variable flip angle method; we therefore adapted the DESPOT1-HIFI approach
proposed by Deoni et al. so that small changes in R1 obtained across different examinations could
be measured [12]. We first scanned a multi-compartment test object containing a range of R1 values
to confirm the accuracy of R1 mapping. We then studied patients following recent minor ischaemic
stroke, since SVD features are prevalent in such patients compared with the wider population [13,14].
Specifically, we aimed to (i) validate B1-insensitive R1 measurement against a reference-standard
technique, (ii) determine whether R1 and R2* changes in the brain are detectable following USPIO
infusion and at one day following infusion, (iii) determine whether residual USPIO is detectable one
month after administration by obtaining an additional R2* measurement (R1 was not measured at this
time point in order to reduce the burden on participants), and (iv) measure blood-normalised R1 and R2*
changes in grey matter (GM), normal-appearing white matter (WM) and white matter hyperintensity
(WMH) tissue regions in this patient group in order to estimate cerebral blood volume and test for
potential extravascular or perivascular USPIO uptake due to inflammation or BBB leak. Blood R1 was
measured in the superior sagittal sinus and used for normalisation of both R1 and R2* changes in tissue,
since R2* changes in blood were spatially heterogeneous and inconsistent across patients.
2. Results
2.1. Compliance, Tolerability and Symptoms
R1 and R2* maps, and structural images were obtained successfully in all 12 patients (mean age
74.7 ± 6.3 years; Table 1). Scan 2 occurred on average 28 h (range: 26–30 h) after scan 1pre for all
patients, while scan 3 took place an average of 31 days (range: 22–36 days) after scan 1pre. Values of
R1 and ∆R1 for one patient at scan 1post were outliers and were excluded from analyses; no signs of
protocol deviations or of unusual observations in relation to this participant were found in the study
records or image header information.
2.2. In Vitro Accuracy of R1 Mapping
R1 measurements in a MRI phantom (test object) obtained using the variable flip angle approach
were inaccurate compared with gold-standard inversion-recovery spin-echo measurements (absolute
difference: 0.03–0.58 s−1; Figure 1a). The errors were largely explained by the spatial flip angle
variation (measured using DESPOT1-HIFI), which was found to be greater than the nominal value
in the five regions with lowest R1 and vice versa. DESPOT1-HIFI R1 measurements corresponded
more closely to gold-standard measurements across the full range of values provided the equation
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of Deichmann et al. [15] was used to model the IR-sGRE signal (absolute difference: 0.01–0.23 s−1;
Figure 1a). Results obtained using a simplified IR-sGRE signal model (absolute difference: 0.01–0.87 s−1;
Figure 1a) were acceptable within the range of R1 found in GM and WM but were inaccurate at the
highest R1 value, which is typical of blood magnetisation following USPIO administration. To explore
this further, the signals predicted by both models and by the full mathematical description by Brix et
al. were calculated as a function of R1 (Figure 1b), demonstrating substantial errors in the simplified
model predictions at high R1 values. Patients’ measurements were therefore obtained using the
DESPOT1-HIFI method with the Deichmann signal model.
Table 1. Patient demographics.
Characteristic (N = 12)
Age (mean ± SD) 74.1 ± 6.7
Male 67% (8)




Ischaemic Heart Disease 8% (1)
History of Smoking 50% (6)
Alcohol Intake (units per week, median and range) 9 (0–30)
NIHSS (median and range) 2 (1–4)
Modified Rankin Score Post Stroke (median and range) 1 (0–2)
Days Post-Stroke (median and range) 48 (31–276)
WMH Volume (mL) (median and range) 12.5 (3.2–46.9)
TIA: transient ischaemic attack; NIHSS: National Institutes of Health Stroke Scale; WMH: white matter hyperintensity.
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Figure 1. (a) Errors in the R1 measurements versus gold-standard inversion-recovery spin-echo
(IRSE) values, measured in a phantom using DESPOT1-HIFI with the Deichmann signal model, an
approximate signal model neglecting effects of the pulse train and using the variable flip a gle method;
(b) Calculated inversion-recovery prepared spoil d radient echo (IR-sGRE) signal (assuming s0 = 100)
for the acquisition parameters given in Table 5 using both the full mathematical description of Brix
et al., the model by Deichmann et al. and the simplified model as described in the text. Note that the
Deichmann prediction is almost identical to that of the Brix model and is consequently not visible.
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2.3. Relaxation Rate Changes Following USPIO Administration
Example parametric maps are shown in Figure 2, illustrating the subtle R1 and R2* changes
observed in patients. R1 increased relative to baseline in all regions at scan 1post and scan 2 (Table 2,
Figure 3a; p < 0.05). R2* also increased in all regions at scan 1post and scan 2 (Table 2, Figure 3b;
p < 0.01). There was a trend towards increasing R1 between scan 1post and scan 2 in all regions, but
this was statistically significant only in blood (p < 0.01) and WMH (p < 0.05); for R2*, a significant
further increase between scan 1post and scan 2 was seen in WM, GM, WMH (p < 0.001) and in stroke
lesions (p < 0.05). Relaxation rates corresponding to each subject, region and time point are provided
as supplementary material.
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The mean change in R2* at scan 3 (one month) was small (0.006–0.327 s−1) and was not statistically
significant in any of the regions. There was no association between changes in the two relaxation rates
∆R1 and ∆R2* immediately following USPIO administration except in WMH (p < 0.05), but there was
a strong association in all regions at 24–30 h (p < 0.01; Table 3, Figure 4).
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Table 2. Mean (standard deviation) relaxation rate values for each region of interest (ROI), averaged
over patients. Statistically significant changes relative to baseline are indicated by * (p < 0.05), ** (p < 0.01)
and *** (p < 0.001).
ROI
R1 (s−1) R2* (s−1)



































19.0 (3.6) 21.4 (2.5) ** 23.9 (4.6) *** 19.3 (3.7)
WM: (normal-appearing) white matter, GM: grey matter, WMH: white matter hyperintensities, SL: stroke lesion.
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Table 3. Linear regression analysis of change in R1 (∆R1) versus change in R2* (∆R2*) at scan 1post
(immediately post-USPIO) and scan 2 (24–30 h post-USPIO). Changes are calculated relative to scan
1pre (pre-USPIO) values. Statistically significant associations are indicated by * (p < 0.05), ** (p < 0.01)
and *** (p < 0.001).
ROI
Scan 1post Scan 2
β0 (s−1) β1 R2 β0 (s−1) β1 R2
WM 2.6 14.2 0.18 2.5 33.4 0.61 **
GM 4.7 14.9 0.06 1.7 69.2 0.70 ***
WMH 2.1 18.7 0.75 * 2.4 25.3 0.73 ***
SL 1.8 47.2 0.34 1.3 56.9 0.64 **
β0: intercept, β1: slope, WM: normal-appearing white matter, GM: grey matter, WMH: white matter hyperintensities,
SL: stroke lesion.
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2.4. Blood-Normalised Relaxation Rate Changes
The blood-normalised relaxation rate changes ∆R1,norm and ∆R∗2,norm (Table 4, Figure 5) did not
change between scan 1post and scan 2 in any of the tissue regions—in other words, the tissue relaxation
rate changes over this period are accounted for by the changes in capillary USPIO concentration
following infusion of the final two-thirds dose, and elimination and redistribution of the contrast
agent. Values were greater in GM than in WM for both measures and time points (p < 0.001). ∆R1,norm
at scan 2 was also greater in WMH and SL versus WM (p < 0.05); there were no other significant
differences between tissues. In general, a narrower distribution of values (expressed as the coefficient
of variation; Table 4) was seen for ∆R∗2,norm compared with ∆R1,norm.
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Table 4. Normalised relaxation rate changes for each ROI, averaged over patients. Coefficients of
variation (%) are shown in parenthesis. Statistically significant differences compared with WM are
indicated by * (p < 0.05), ** (p < 0.01) and *** (p < 0.001).
ROI
∆R1,norm ∆R*2,norm
Scan 1post Scan 2 Scan 1post Scan 2
WM 0.0084 (45) 0.0087 (43) 0.97 (16) 0.93 (14)
GM 0.0239 (21) *** 0.0204 (16) *** 1.86 (11) *** 1.85 (14) ***
WMH 0.0153 (68) 0.0148 (50) * 0.96 (22) 0.97 (17)
SL 0.0125 (34) 0.0151 (38) * 1.17 (26) 1.21 (41)
WM: normal-appearing white matter, GM: grey matter, WMH: white matter hyperintensities, SL: stroke lesion.
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3. Discussion
In this study we administered USPIO and performed R1 and R2* mapping in patients with
SVD. The USPIO were tolerated, and importantly, we found no evidence of retention at one month.
We established a protocol for assessing contrast uptake, including R1 mapping in the presence of the
substantial B1 inhomogeneity seen at 3T and validated this in vitro. Using relaxometry, we were able
to detect changes in both normal and diseased tissues immediately after USPIO administration at one
third of the standard dose, and at one day following administration of the full dose. Blood-normalised
changes in the relaxation rates in WM and GM regions were consistent with expected differences
in cerebral blood volume, and did not change further at 24–30 h, which implies that no detectable
parenchymal uptake occurred on this timescale. Changes in R1 and R2* were strongly correlated
at 24–30 h; the weak association immediately post-contrast is likely due to fewer subjects receiving
scan 1post (n = 8). Narrower distributions were seen for R2*-compared with R1-derived quantities,
suggesting that the former may be a more sensitive marker of uptake.
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Few previous studies have employed quantitative MRI to assess USPIO uptake in the brain, and
we are unaware of any such application in cerebral small vessel disease patients. A small number of
studies have administered USPIO in stroke patients, with observations of signal change, mainly on
T1w images, that can be cautiously ascribed to inflammatory uptake in some stroke lesions within
1–2 weeks following acute ischaemic stroke [16–19]. A key advantage of using quantitative relaxometry,
as here, is that uptake occurring over a longer time period can be measured; approaches based on
changes in signal intensity are restricted to qualitative interpretation or to measuring uptake during
the examination (as in DCE and dynamic susceptibility contrast MRI). By performing quantitative
relaxometry including blood pool measurements, we were also able to determine whether the observed
changes could be explained by intra-vascular (as opposed to parenchymal) USPIO uptake.
The approach presented in this paper relies on accurate volumetric measurement of R1 and R2*.
Through selection of an appropriate acquisition strategy and careful signal modelling, we were able
to measure inter-examination R1 changes, obtaining GM, WM and venous blood R1 values similar
to those reported in the literature [20–22]. While the alternative variable flip angle (VFA) method is
faster than DESPOT1-HIFI (since the additional IR-sGRE scans are relatively time-consuming), the
former approach yields parameter maps that are strongly affected by spatial variation in the flip
angle, which can be substantial at 3T and/or when slab-selective excitation pulses are used. Our
phantom measurements confirmed the accuracy of DESPOT1-HIFI across a range of R1 provided
appropriate signal models are used. Alternatively, it is possible to reduce the scan time by combining
VFA acquisition with a technique that directly maps the flip angle, such as actual flip angle imaging
(AFI) [23], but reliable flip angle mapping sequences are not widely available on commercial MRI
scanners. R2* values are necessarily protocol-dependent and are affected by macroscopic B0 field
inhomogeneities, and there is no accepted gold-standard method. However, the values measured in
thalamus at baseline were similar to those reported previously in volunteers [24,25].
As expected, both R1 and R2* increased following USPIO administration. At one-month post-
infusion, R2* had returned to baseline with no statistically significant changes detected. The average
one-month changes in R2* corresponded to 0.2% (WM), 3.4% (GM), 1.2% (WMH) and 6.7% (SL) of the
average changes measured at 24–30 h, implying elimination or near-elimination of ferumoxytol from
the regions measured on this timescale.
Although R1 and R2* increases were detected in the brain tissue of all patients following USPIO
administration, such measurements do not distinguish between USPIO in the blood pool from uptake
in parenchyma. We therefore obtained additional measurements immediately after infusing a third of
the full dose, at which point it is reasonably assumed that any uptake is intravascular and that the
normalised relaxation rate changes, ∆R1,norm and ∆R∗2,norm, are respectively equivalent or proportional
to the cerebral blood volume fraction. ∆R1,norm measurements were consistent with plasma volume
fraction (vp) measurements obtained in a similar patient group by DCE-MRI [6], and were greater
in GM than in WM as expected. A similar pattern was seen for ∆R∗2,norm measurements but there
was no significant difference between WM and WMH values. Varallyay et al. used changes in T2*w
signal intensity to assess relative CBV in patients with a variety of brain pathologies [8]. The approach
described here extends this by measuring both R1 and R2*, and by normalising for blood-pool USPIO
concentration, thereby enabling between as well as within-subject comparison.
Neither normalised relaxation rate changed significantly at 24–30 h following USPIO infusion.
This suggests that there was no detectable parenchymal uptake—for example, due to accumulation of
inflammatory cells or BBB leak—and that the signal changes observed are explained by the blood-pool
uptake alone. In the event of parenchymal uptake occurring, there would likely be increased ∆R1,norm
and ∆R∗2,norm at 24–30 h. However, it is important to note that our sample size was small and that
any generalised chronic neuroinflammation in SVD is likely to be subtle compared with that found in
some diseases of the large arteries. Larger studies, ideally with histological or biochemical validation,
are required to draw biological conclusions. Finally, we observed a strong linear association between,
∆R1,norm and ∆R∗2 at 24–30 h, suggesting that either quantity can be used to assess uptake.
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Advantages of our work include the use of two quantitative relaxometry methods, additional
post-contrast measurement to differentiate blood-pool and parenchymal USPIO uptake, and a final
measurement to confirm elimination of ferumoxytol from the brain. Our R1 mapping protocol was
validated in vitro and is resistant to B1 inhomogeneity. In contrast to acute ischaemic stroke, where
inflammation may be directly visualised in the acute and sub-acute phases, chronic inflammation in
SVD is likely to be more subtle and diffuse. It is therefore important to establish sensitive methods
such as these for detecting changes that may not be radiologically visible. We recruited patients with
past minor stroke including lacunar stroke since these subjects typically have a higher burden of small
vessel disease features and a small index infarct, which can easily be separated from the other tissues
of interest. Patients were scanned weeks or months following the index stroke, which also minimised
the effect of any acute stroke changes on the background brain condition. The main limitation of this
pilot study is the sample size, which precludes firm biological inferences.
Our data suggest that future studies of SVD (and other pathologies) using USPIO contrast agents
would benefit from obtaining quantitative relaxation rate maps including immediately post-infusion
to differentiate intravascular and parenchymal uptake. With regard to R1 versus R2*-based approaches,
there are theoretical grounds for preferring an R1-based technique. First, the concentration dependence
is simpler to model compared with R2*, subject to some of the standard assumptions implicit in
DCE-MRI analysis (e.g., fast water exchange regime). Second, it is more straightforward to measure
R1 than R2* in blood vessels. However, the tissue R1 changes observed in this study were subtle
and had wider distributions compared with corresponding R2* changes. This is partly due to the
combined intravascular and extravascular effects of blood-pool contrast in R2* sequences, which leads
to greater sensitivity in fMRI and perfusion imaging applications, and the superparamagetic nature
of USPIO particles. A second challenge is the optimisation of R1 mapping for the wide range of
values observed following USPIO administration. In future studies, it may be expedient to increase
the precision of R1 measurement (for example by sacrificing spatial resolution) or to focus on R2*
measurement where time is limited. For the latter approach, it is nevertheless useful to obtain R1
in blood for normalisation, which could be achieved more rapidly using a single-slice technique
in place of a whole-brain measurement protocol [22]. A caveat is that while parenchymal uptake
is expected to increase R1, the effect on R2* is more difficult to determine due to a more complex
dependence on concentration, distribution and geometry [26,27]. Future studies should also assess CBV
and parenchymal uptake in relation to small vessel disease severity, including WMH and enlarged
perivascular space burdens. In conclusion, our work advances the methodology for probing the
neurovasculature in SVD and for quantitatively assessing uptake of USPIO, paving the way for further
use of these contrast agents in cerebral small vessel disease research and in other pathologies.
4. Materials and Methods
4.1. Participants
Twelve patients were recruited with a history of non-disabling minor ischaemic stroke occurring
a minimum of one month previously. Patients were recruited from the regional clinical stroke
service as described previously [6,28], and from our register of patients with a clinical diagnosis
of minor non-disabling ischaemic stroke in the past five years. “Non-disabling” was defined as not
requiring assistance in activities of daily living (modified Rankin score ≤ 3). We included those with
diabetes mellitus, hypertension and other vascular risk factors as long as these were well-controlled.
We excluded patients with unstable diabetes, chronic kidney disease with estimated glomerular
filtration rate < 30, other neurological disorders, or other life threatening medical conditions. We also
excluded patients unable to give consent, with contraindications to MRI, and who had haemorrhagic
stroke (but not haemorrhagic transformation of an infarct). The study was conducted following
Research Ethics Committee approval (South East Scotland Research Ethics Committee 01, reference
Int. J. Mol. Sci. 2019, 20, 776 10 of 16
14/SS/1081, 27 November 2014) and according to the principles expressed in the Declaration of
Helsinki. All subjects gave written informed consent.
4.2. MRI and USPIO Administration
4.2.1. Patient Study
Participants were scanned using a 3-T Siemens Magnetom Verio MRI scanner with a 12-channel
receive-only head coil (Siemens Healthcare, Erlangen, Germany). Scans took place at baseline
(“scan 1pre”), which was immediately followed by USPIO (ferumoxytol; 4.0 mg/kg) infusion, at 24–30 h
following infusion (“scan 2”) and at four weeks following infusion (“scan 3”). Eight of the patients
were scanned additionally immediately after 1/3 of the total USPIO dose had been administered
(“scan 1post”), with the remainder of the dose administered immediately after the scan. USPIO was
administered outside of the scanner and was made up using a vial of ferumoxytol (30 mg/mL)
diluted in up to 100 mL of sterile 0.9% sodium chloride to achieve a final concentration for infusion of
2–8 mg/mL, as recommended by the manufacturer. All participants received a final dose of 4.0 mg/kg,
infused via a venous cannula sited in the participant’s forearm over at least 15 min with participants in
a reclined or semi-recumbent position. A saline flush was administered following the infusion. Blood
pressure was monitored and a physician was present at the time of administration and for at least
30 min afterwards to monitor the patient and treat any reactions.
Structural imaging consisted of T1w, T2w, GRE and T2-weighted FLAIR acquisitions. R1 and flip
angle were measured using the DESPOT1-HIFI method [12] at scans 1pre, 1post and 2, consisting of
two 3D inversion-recovery prepared spoiled gradient echo sequences (IR-sGRE) and three 3D spoiled
gradient echo sequences (sGRE) with different flip angles. R2* was measured using a 3D multi-echo
spoiled gradient echo sequence (ME-sGRE) at all four scans. MRI sequence parameters are provided
in Table 5.
4.2.2. Phantom Validation
To verify the accuracy of the DESPOT1-HIFI protocol for a range of R1 values, we scanned
a multi-compartment custom MRI phantom with a range of R1 [29]. This phantom consisted
of nine sealed 10 mL syringes containing 0.05, 0.07, . . . and 0.21 mM MnCl2 in distilled water.
The phantom container was filled with 1.5 g/L CuSO4 and 3.6 g/L NaCl solution to increase the
coil loading, reduce susceptibility artefacts around the syringes and to provide a compartment
with short T1 to mimic longitudinal relaxation in blood vessels following contrast injection [29].
Gold-standard measurements were obtained using a single-slice inversion-recovery spin-echo pulse
sequence (TR/TE/TI = 1550/11/[30, 330, 730, 1130, 1530] ms). Since there is no accepted reference
method for measuring R2* and the multi-echo spoiled gradient echo sequence is regarded as the
standard method, we did not evaluate this sequence in vitro; however, phantom experiments can be
used to evaluate repeatability, reproducibility and relaxivity properties [30].
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15 - 240 × 240 256 (AP) × 192 (LR) 72 × 2 2 7:08 11.1% slice oversampling
DESPOT1-HIFI
Axial 3D IR-sGRE 1190 2.3 5 1000
240 × 240 256 (AP) × 192 (LR) 72 × 2 -
3:50
11.1% slice oversampling;
echo-spacing = 4.5 ms for
IR-sGRE
Axial 3D IR-sGRE 1 632 2.3 5 450 2:03
Axial 3D sGRE 5.7 2.5 12 - 1:29
Axial 3D sGRE 5.7 2.5 5 - 1:29
Axial 3D sGRE 5.7 2.5 3 - 1:29
GRE Axial 3D gradient echo 40 20 15 - 240 × 240 320 (AP) × 256 (LR) 48 × 3 2 5:35 25.0% slice oversampling
T1w Sagittal IR-sGRE 2300 2.98 9 1100 256 × 256 256 × 256 208 × 1 2 5:21 23.1% slice oversampling
T2w Axial 2D PROPELLER 11,400 120 90 - 240 384 48 × 3 - 4:24 -
1 TR/TI = 832/650 ms for subjects 1 to 6; TR: repetition time; TE: echo time; FA: flip angle; TI: inversion time; FOV: field of view; AP: anterior/posterior; LR: left/right.
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4.3. Image Processing and Analysis
4.3.1. R1 Mapping
To generate R1 parametric maps (Figure 1a), the signals of the sGRE and IR-sGRE scans were
corrected for intensity scaling imposed by the scanner. To account for motion between the scans, all
were co-registered to the first volume using rigid body registration (FSL FLIRT [31]). Reference [12]
recommends modelling of the IR-sGRE signal under the assumption that the readout pulse trains
do not influence the recovery of longitudinal magnetisation; for IR-sGRE with perfect inversion, this
assumption leads to the following approximation for the steady-state signal:
SIR−sGRE = S0
1 − 2e−R1TIeff + e−R1TR
1 + e−R1TR
sin κβ (1)
where s0 represents the maximum possible signal, TIeff is the effective inversion time (i.e., the time
between the inversion pulse and the excitation pulse for acquisition of the central k-space line),
β is the flip angle corresponding to pulses in the readout train and k is the ratio of actual and
nominal flip angles. To test the validity of this approximation, phantom data was modelled using
both Equation (1) above and using the signal model expressed by Equation (13) in the article by
Deichmann et al. [15], which does not make this assumption and which very closely approximates the
complete pulse-by-pulse description derived by Brix et al. [32] The following additional characteristics
of the IR-sGRE sequence implementation were taken into consideration: (i) the inversion pulse is
non-selective and B1-insensitive, therefore complete inversion was assumed, and (ii) all k-space lines
in the slice direction were sampled linearly in a single pulse train, thus the signal magnitude was




1 − e−R1TR cos κβ sin κβ (2)
where T2* decay is assumed to be negligible at the short echo times used. s0, R1 and k were determined
using in-house Matlab code (https://github.com/mjt320/HIFI) incorporating the Matlab lsqcurvefit
function (MathWorks, Natick, MA, USA) to minimise the sum-of-square differences between the
measured and predicted signals for each voxel. All three parameters were constrained to be positive.
Additionally, R1 maps were obtained by fitting the sGRE phantom images alone with k fixed as unity
in order to assess the accuracy of the widely-used variable flip angle technique.
4.3.2. R2* Mapping
To generate R2* maps (Figure 1b), multi-echo data was fit as described above using in-house
Matlab code (https://github.com/mjt320/T2Star) but without constraints and using the signal model
si = sTE=0e−R
∗
2 TEi , where si and TEi are the signal and echo time for echo i, respectively, and sTE=0 is
the steady-state signal at zero echo time. To avoid fitting low SNR voxels and to reduce bias due to the
noise “floor” at long TE, voxels and individual data points with intensities close to the noise level were
excluded from the fitting using empirically determined thresholds.
4.3.3. Structural Image Processing
Structural MR images were linearly co-registered to the gradient echo (GRE) image obtained
at scan 1pre using a two-step rigid-body registration (FSL FLIRT [31]). The brain was extracted
automatically using FSL BET2 [33] with an empirically-determined weighted average of the
T2-weighted (T2w) and GRE images as input, after correcting both images for the effects of coil
sensitivity inhomogeneities and linearly normalising their intensities [34]. The intracranial volume
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mask was refined by nullifying voxels with standard intensity scores below −1.2 in the GRE image
and filling any “holes” in the resultant mask.
GM regions of interest (ROIs) representative of the deep grey matter were manually drawn as
circular regions within the left and right thalamus on slices containing these structures, carefully
avoiding tissue boundaries, lesions and vessels.
WM and WMH segmentation masks were obtained automatically using multispectral data fusion
and a two-step Gaussian clustering followed by the computation of the Bayesian conditional probability
for each cluster [35]. The first clusterisation operated on a four-dimensional array (three spatial
dimensions plus sequence) formed by the combination of the brain-extracted T1w, T2w and FLAIR
images, and generated likelihood maps of pure cerebrospinal fluid (CSF), normal-appearing white
matter and a mixed tissue class containing features with high T2w and low T1w signal, including GM,
WMH, SL and perivascular spaces. Deep GM voxels were removed from this map using a pipeline [36]
that employs FMRIB Software Library tools and a cohort-relevant template; cortical GM was also
removed via non-linear registration (NiftyReg, https://sourceforge.net/projects/niftyreg/) of a white
matter template (http://datashare.is.ed.ac.uk/handle/10283) to subject space. A second clusterisation
using GRE and FLAIR images was used to extract the FLAIR hyperintensities (i.e., SL and WMH) from
any remaining elements of the mixed tissue class. Manual editing was then used to separate SL from
WMH, guided by radiological reports. Likelihood maps were thresholded empirically to generate
binary masks containing pure tissues with minimal contamination and were eroded to further reduce
partial volume effects and the effects of any misregistration. Example masks and ROIs are shown in
Figure 6.
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4.3.4. Quantitative Image Processing
R1 and R2* maps were spatially co-registered to the first time point using NiftyReg (non-linear
transformation) and using the first image acquired for R1 and the first echo image of the R2* scan.
To obtain R1 values in blood, regions were manually drawn within the superior sagittal sinus on three
neighbouring slices, located centrally within the slab. Other ROIs were transformed into the parameter
map space and used to sample R1 and R2* values. Median values for each patient and ROI were used
in further analyses.
To account for inter-patient and inter-visit variation in blood-pool USPIO concentration, the
normalised change in R1 was calculated at each post-USPIO time point as ∆R1,norm = ∆R1/∆R1,blood,
where ∆ indicates the change relative to baseline (i.e., scan 1pre). Assuming a linear relationship
between R1 and USPIO concentration, and assuming that USPIO is restricted to the blood pool
immediately after infusion, this quantity approximates the cerebral blood volume fraction (CBV).
The normalised R2* change was also calculated. However, R2* values and changes in the superior
sagittal sinus were spatially heterogeneous and inconsistent across patients, presumably due to
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the possibly complex [37], and to our knowledge, unknown dependence of R2* on venous USPIO
concentration, vessel morphology, vessel orientation and location within the vessel [38]; therefore,
blood R1 values were used for normalisation and the ratio ∆R∗2,norm = ∆R
∗
2/∆R1,blood was calculated,
which is expected to be approximately proportional to the CBV immediately after infusion.
4.4. Statistics
Differences in relaxation rate between different time points or tissues were assessed using the
two-sided paired t-test. Associations between R1 and R2* changes were explored using linear regression
and Pearson’s correlation coefficient. A significance threshold of p < 0.05 was used.
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USPIO ultrasmall superparamagnetic particles of iron oxide
GM grey matter
WM white matter
WMH white matter hyperintensities
CBV cerebral blood volume
BBB blood-brain barrier
SL stroke lesion
ROI region of interest
IR-sGRE inversion-recovery prepared spoiled gradient echo
sGRE spoiled gradient echo
MRI magnetic resonance imaging
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